期刊文献+

卵巢低、高级别浆液性癌的临床病理分析及Pax2、p53和Ki-67表达的意义 被引量:18

Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas
原文传递
导出
摘要 目的初步评估卵巢浆液性癌的两级分级系统在病理诊断和预后判断中的应用价值,探讨低、高级别浆液性癌Pax2、p53和Ki-67的表达及其与预后的相关性。方法依照两级分级系统对卵巢浆液性癌进行分级,分别选取低级别癌38例,高级别癌100例,观察其临床病理特点,并采用免疫组织化学EnVision法检测癌组织中Pax2、p53和Ki-67的表达情况。结果(1)低级别组的总生存时间、无病生存时间和5年生存率均显著优于高级别组(P〈0.05)。(2)低级别组Pax2的阳性率显著高于高级别组(65.8%比13.0%,P〈0.05),而p53强阳性率显著低于高级别组(13.2%比55.0%,P〈0.05),Ki-67阳性指数显著低于高级别组(13.7%比42.1%,P〈0.05)。(3)Pax2阳性组的总生存时间和5年生存率均显著优于阴性组(P〈0.05),而无病生存时间的差异无统计学意义(P〉0.05)。p53和Ki-67阳性指数与生存时间的差异无统计学意义(P〉0.05)。结论两级分级系统对卵巢浆液性癌的预后判断有提示意义,在临床病理诊断中具有可行性。Pax2、p53和Ki-67在卵巢低、高级别浆液性癌中的表达差异有统计学意义。与p53和Ki.67相比,Pax2更有可能成为卵巢浆液性癌的一个预后相关指标。 Objective To evaluate the two-tier system for the grading of ovarian serous carcinomas, and to analyze Pax2, p53, Ki-67 protein expression and their prognostic values for low- and high-grade ovarian serous carcinomas. Methods A total of 38 cases of low-grade and 100 cases of high-grade ovarian serous carcinomas were selected based on the two-tier grading system. Immunohistochemistry was used to detect Pax2, p53 and Ki-67 protein expression in all cases. Correlation of the two-tier system with immunohistochemical results and prognostic parameters were performed. Results ( 1 ) The overall survival, disease-free survival and 5-year survival rates were significantly higher in the low-grade serous carcinoma cases than in the high-grade cases ( P 〈 0. 05 ). (2) SignifiCant differences in protein expressions were found between the low- and high-grade serous carcinomas. The high-grade serous carcinomas had a significantly higher expression level of p53 (55.0% vs 13.2% , P 〈0. 05) and Ki-67 (42. 1% vs 13.7% , P 〈0. 05), while low-grade carcinomas had a significantly higher expression level of Pax2 (65.8% vs 13.0%, P 〈 0. 05 ). ( 3 ) Pax2 positive cases had a significantly better overall survival and 5-year survival rates than Pax2 negative cases ( P 〈 0. 05 ). The expressions of p53 and Ki-67 were found to have little correlation with overall survival and disease-free survival(P 〉 O. 05 ). Conclusions The two-tier system for the grading of ovarian serous carcinomas has a good prognostic value. There are significantly differences in expressions of Pax2, p53 and Ki-67 between low- and high-grade ovarian serous carcinomas. Compared with p53 and Ki-67, Pax2 is likely a better prognostic indicator for ovarian serous carcinoma.
出处 《中华病理学杂志》 CAS CSCD 北大核心 2011年第8期511-516,共6页 Chinese Journal of Pathology
关键词 卵巢肿瘤 肿瘤分期 免疫组织化学 预后 Ovarian neoplasms Neoplasm staging Immunohistochemistry Prognosis
  • 相关文献

参考文献23

  • 1Silverberg SG. Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol, 2000, 19( 1 ) : 7-15.
  • 2Singer G, Kurman RJ, Chang HW, et al. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol, 2002, 160 (4) : 1223-1228.
  • 3Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol, 2004, 28 (4) : 496 -504.
  • 4Shih leM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol, 2004, 164(5) : 1511-1518.
  • 5Tong GX, Chiriboga L, Hamele-Bena D, et al. Expression of PAX2 in papillary serous carcinoma of the ovary : immunohistochemical evidence of fallopian tube or secondary Mtillerian system origin? Mod Pathol, 2007, 20(8) : 856-863.
  • 6O'Neill C J, Deavers MT, Malpica A, et al. An immunohistechemical comparison between low-grade and high- grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, FIER-2/neu, and C-KIT in high-grade neoplasms. Am J Surg Pathol, 2005, 29(8) : 1034-1041.
  • 7Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist, 2002, 7 ( Snppl 5 ) : 20-28.
  • 8Seidman JD, Horkayne-Szakaly I, Cosin JA, et al. Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum. Gynecol Oncol, 2006, 103(2) : 703-708.
  • 9Vang R, Shih IeM, Kurman RJ. Ovarian low-grade and high- grade serous carcinoma : pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol, 2009, 16(5) : 267-282.
  • 10Ayhan A, Kurman R J, Yemelyanova A, et al. Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis. Am J Surg Pathol, 2009, 33(8) : 1220-1224.

二级参考文献18

  • 1Shih IM,Kurman RJ.Ovarian tumorigenesis:a proposed model based on morphological and molecular genetic analysis.Am J Pathol,2004,164(5):1511-1518.
  • 2Gilks CB,Prat J.Ovarian carcinoma pathology and genetics:recent advances.Hum Pathol,2009,40 (9):1213-1223.
  • 3Malpica A,Deavers MT,Lu K,et al.Grading ovarian serous carcinoma using a two-tier system.Am J Surg Pathol,2004,28(4):496-504.
  • 4Scully RE.World Health Organization classification and nomenclature of ovarian cancer.Natl Cancer Inst Monogr,1975,42:5-7.
  • 5Armstrong DK.Relapsed ovarian cancer:challenges and management strategies for a chronic disease.Oncologist,2002,7 Suppl 5:20-28.
  • 6Rustin GJ,Nelstrop AE,Tuxen MK,et al.Defining progression of ovarian carcinoma during follow-up according to CA 125:a North Thames Ovary Group Study.Ann Oncol,1996,7(4):361-364.
  • 7Rustin GJ,Nelstrop AE,Crawford M,et al.Phase Ⅱ trial of oral altretamine for relapsed ovarian carcinoma:evaluation of defining response by serum CA125.J Clin Oncol,1997,15 (1):172-176.
  • 8Hill DA,Chiosea S,Jamaluddin S,et al.Inducible changes in cell size and attachment area due to expression of a mutant SWI/SNF chromatin remodeling enzyme.J Cell Sci,2004,117 (Pt24):5847-5854.
  • 9Gilks CB,Vanderhyden BC,Zhu S,et al.Distinction between serous tumors of low malignant potential and serous caroinonas based on global mRNA expression profiling.Gynecol Oncol,2005,96(3):684-694.
  • 10Meinhold-Heerlein I,Bauerschlag D,Hilpert F,et al.Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential.Oncogene,2005,24 (6):1053-1065.

共引文献20

同被引文献141

引证文献18

二级引证文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部